Starting Dose and Laboratory Monitoring for Laroxyl (Amitriptyline) in Depression
For depression in adults, start Laroxyl (amitriptyline) at 25 mg at bedtime, titrating by 25 mg every 3-7 days as tolerated to a goal dose of 75-150 mg nightly, with baseline and periodic ECG monitoring being the most critical laboratory assessment. 1, 2
Starting Dose
The recommended starting approach is:
- Initial dose: 25 mg at bedtime 2
- Titration: Increase by 25 mg increments every 3-7 days until therapeutic benefit or dose-limiting side effects occur 3
- Goal dose: 75-150 mg nightly (or 1-1.5 mg/kg at bedtime) 1, 2
- Maximum dose: 150 mg daily 1
Slow titration is better tolerated and reduces the burden of anticholinergic and cardiovascular side effects that commonly occur with amitriptyline 2. The medication should be dosed at night to leverage its sedating properties 1, 2.
Laboratory Monitoring
Essential Monitoring
Baseline ECG is mandatory before initiating amitriptyline, particularly because:
- Amitriptyline causes QT prolongation in a dose-dependent manner 4
- It can cause cardiac conduction abnormalities, including increased PQ and QRS intervals 5
- Cardiovascular effects are especially pronounced in elderly patients (age >60 years) 5
Additional Monitoring Considerations
While not explicitly required by guidelines for depression treatment specifically, consider:
- Baseline liver function tests: Amitriptyline can cause asymptomatic mild transaminase elevations (0.5-3% of patients), though this is lower risk than with other tricyclics 4
- Therapeutic drug monitoring (TDM): Plasma levels of amitriptyline plus nortriptyline (its active metabolite) can be measured if response is inadequate at conventional doses 6, 7
Clinical Monitoring Timeline
- Week 1-2: Assess for suicidal ideation, agitation, or unusual behavioral changes (FDA advisory for all antidepressants) 9
- Weeks 1-4: Monitor for anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision), sedation, orthostatic hypotension, and tachycardia 1, 2, 5
- Week 6-8: Assess therapeutic response; if inadequate, consider dose adjustment or alternative therapy 9
- 4-9 months: Continue treatment after satisfactory response for first episode 9
Critical Warnings
Amitriptyline has significant anticholinergic and cardiovascular side effects compared to newer antidepressants 10, 11. It should be used with particular caution in:
- Patients with cardiac disease or arrhythmia history 1
- Elderly patients (consider lower starting doses of 10 mg) 3
- Patients with glaucoma, urinary retention, or seizure disorders 3
Orthostatic hypotension without compensatory heart rate increase is common and persistent throughout treatment 5, requiring patient education about fall risk.
The evidence strongly supports that amitriptyline is efficacious for depression (OR 2.67 vs placebo) 10, but the trade-off is a higher side effect burden, with more patients withdrawing due to adverse effects (OR 4.15) 10. This makes careful dose titration and monitoring essential for successful treatment.